ReviewJournal of gastroenterology and hepatology2013
Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis.
Review in Journal of gastroenterology and hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives.Biomedicines · 2022Review
- Resident macrophages of the lung and liver: The guardians of our tissues.Frontiers in immunology · 2022Review
- Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach.Cancers · 2021Review
- Article
- Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-PPAR research · 2021Article
- LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis.Journal of translational medicine · 2020Article
- Pattern Recognition Receptors: Significance of Expression in the Liver.Archivum immunologiae et therapiae experimentalis · 2020Review
- Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities.Frontiers in medicine · 2020Review
- Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease.Translational gastroenterology and hepatology · 2020Review
- Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2019Article
- The immunology of hepatocellular carcinoma.Nature immunology · 2018Review
- New insights into Nod-like receptors (NLRs) in liver diseases.International journal of physiology, pathophysiology and pharmacology · 2018Review
- Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.JCI insight · 2017Review
- Role of alcohol in the development and progression of hepatocellular carcinoma.Hepatic oncology · 2016Review
- Inflammasome activation and function in liver disease.Nature reviews. Gastroenterology & hepatology · 2015Review
- Chronic alcohol consumption potentiates the development of diabetes through pancreatic β-cell dysfunction.World journal of biological chemistry · 2015Review
- TLR3/4 signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.Experimental and molecular pathology · 2014Article
- Immune dysfunction in cirrhosis.World journal of gastroenterology · 2014Review
- Role of innate immunity in the development of hepatocellular carcinoma.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The similar histopathological characteristics of alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), and the crucial role of the innate immune response in both conditions may lead to the assumption that ASH and NASH represent the same pathophysiological entities caused by different risk factors. In this review paper, we elaborate on the pathophysiological differences between these two entities and highlight the disease-specific involvement of signaling molecules downstream of the Toll-like receptor 4, and the differential mechanism by which the inflammasome contributes to ASH versus NASH. Our findings emphasize that ASH and NASH have disease-specific mechanisms and therefore represent distinct biological entities. Further studies are needed to dissect the emerging differences in pathogenesis of these two conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.